CEL-SCI Corporation news

   Watch this stock
Showing stories 1 - 8 of about 8   

Articles published

CVM 1.89 +0.09 (4.70%)
price chart
CEL-SCI Announces Update on Ongoing Arbitration against Former Clinical ...
On October 3, 2017, Lake Whillans Litigation Funding and CEL-SCI agreed to give an incentive to the law firm, Wilk Auslander, which is handling the case for CEL-SCI against the former CRO. Pursuant to this new arrangement, Lake Whillans has agreed to ...
CEL-SCI Granted European Patent for Multikine's Mechanism of Action in Making ...
VIENNA, Va.--(BUSINESS WIRE)--CEL-SCI Corporation (NYSE American: CVM) announced today that the European Patent Office has issued a new patent to CEL-SCI for its lead investigational immunotherapy, Multikine* (Leukocyte Interleukin, Injection), which ...
The Fundamental Case for and Against CEL-SCI Corporation (CVM)  StockNewsGazette
Cel-Sci says arbitration with inVentiv nearing an end
The arbitration relates to a Phase III trial of Cel-Sci's candidate immunotherapy Multikine (Leukocyte Interleukin, Injection) in the treatment of patients suffering squamous cell carcinoma of the head and neck.
Tracking the one year Price Target on CEL-SCI Corporation (CVM)
Cel-Sci Corporation (NYSEMKT:CVM) stock ended the last trade transaction at $1.71. The 50-Day Moving Average price noticed at $1.79 and the 200 Day Moving Average price is at $1.21.
How Insiders and Institutions are Trading Level 3 Communications, Inc. (LVLT)
Recent insider trends for Level 3 Communications, Inc. (NYSE:LVLT) have caught the attention of investors. Insider activity is often a strong indicator of future performance in a stock, and if the data on LVLT is anything to go by, investors should pay ...
The Top Three Holders Of Idera Pharmaceuticals, Inc. (IDRA)
Idera Pharmaceuticals, Inc. disclosed in a document filed with the US Securities and Exchange Commission (SEC) that Director, 10% Owner Pillar Invest Corp has sold 450,815 shares of Idera Pharmaceuticals, Inc. (IDRA) in trading session dated May. 01 ...
Hot On The Charts: KalVista Pharmaceuticals, Inc. (KALV), Sage Therapeutics ...
KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) traded at an unexpectedly high level on 11/10/2017 when the stock experienced a -1.86% loss to a closing price of $10.
Price target analysis on MiMedx Group, Inc. (MDXG)
MiMedx Group, Inc (NASDAQ:MDXG) climbed +0.72 points or +6.12% on daily trading volume of 2.52 million shares over it average volume on 10/4/2017.